The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists

Australas Psychiatry. 2023 Apr;31(2):190-194. doi: 10.1177/10398562231156684. Epub 2023 Feb 13.

Abstract

Objective: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies.

Method: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions.

Results: Fifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future.

Conclusion: Considering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists.

Keywords: Psychedelics; attitudes; prescription; psychiatrists; survey.

MeSH terms

  • Australia
  • Cross-Sectional Studies
  • Hallucinogens* / therapeutic use
  • Humans
  • New Zealand
  • Prescriptions
  • Psychiatry* / education
  • Surveys and Questionnaires

Substances

  • Hallucinogens